6622 — Zhaoke Ophthalmology Share News
0.000.00%
- HK$1.19bn
- HK$662.62m
- CNY31.97m
Brief: Zhaoke Ophthalmology Says Positive Top-Line Data From Phase 3 Pivotal BRIO-I Trial Of Brimochol PF
Brief: Zhaoke Ophthalmology Posts FY Loss Of RMB407.3 Mln
Brief: Zhaoke Ophthalmology Enters Distribution Agreement With Kwangdong Pharmaceutical
Brief: Zhaoke Ophthalmology Has Not Placed Any Deposit With SVB Or Its Affiliates As Of March 13
Brief: Zhaoke Ophthalmology Obtains Marketing Authorization For Bimatoprost Timolol Eye Drop
Brief: Zhaoke Ophthalmology Says Cyclosporine A Ophthalmic Gel Passed On-Site Regulatory And Clinical Trial Inspections By NMPA
Brief: GIC Private Limited's Long Position In Ordinary Shares Of Zhaoke Ophthalmology Falls To 12.99% - HKEX Filing
Brief: Zhaoke Ophthalmology Announces Distribution Agreement To Commercialize Tono-I In Greater China
Brief: Zhaoke Ophthalmology Announces Positive Results From Phase III Champ Study Of NVK002
HY Loss Rmb161.0 Million Versus Loss Of Rmb1.99 Billion
Brief: Zhaoke Ophthalmology Says New Drug Application Of Cyclosporine A Ophthamic Gel Accepted By Center For Drug Evaluation
Brief: Zhaoke Ophthalmology Says FY Loss RMB1.76 Bln Vs Loss Of RMB670 Mln
Brief: Zhaoke Ophthalmology Says It Signed LoI With Life Science Solutions Affiliate Of Yidu Tech
Brief: Zhaoke Ophthalmology Says Ind Application Of Nvk-002 Approved By CDE Of NMPA Of China
Brief: Zhaoke Ophthalmology Says Drug Candidates Passed On-Site Inspection For Drug Registration In China
Brief: Zhaoke Ophthalmology Says HY Loss Rmb1.99 Billion Versus Loss Of Rmb66.6 Million
Brief: Zhaoke Ophthalmology Says Phase III Trial Of Cyclosporine A Ophthalmic Gel Met Primary Endpoint
Brief: Zhaoke Ophthalmology Says Got Approval For Import Of NTC010 (Leviosa)
Brief: Zhaoke Ophthalmology Says IND Application Of Nvk-002 For Phase Iii Trial In China Accepted For Review